TY - JOUR
T1 - Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel
AU - Sato, Yasunori
AU - Yamamoto, Noboru
AU - Kunitoh, Hideo
AU - Ohe, Yuichiro
AU - Minami, Hironobu
AU - Laird, Nan M.
AU - Katori, Noriko
AU - Saito, Yoshiro
AU - Ohnami, Sumiko
AU - Sakamoto, Hiromi
AU - Sawada, Jun Ichi
AU - Saijo, Nagahiro
AU - Yoshida, Teruhiko
AU - Tamura, Tomohide
N1 - Funding Information:
Supported by the Program for the Promotion of Fundamental Studies in Health Sciences from National Institute of Biomedical Innovation (ID 05-41).
PY - 2011/1
Y1 - 2011/1
N2 - PURPOSE: Our goal was to identify candidate polymorphisms that could influence overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with carboplatin (CBDCA) and paclitaxel (PTX). METHODS: Chemotherapy-naïve stage IIIB or IV NSCLC patients treated with CBDCA (area under the curve = 6 mg/mL/min) and PTX (200 mg/m2, 3-hour period) were eligible for this study. The DNA samples were extracted from peripheral blood mononuclear cells before treatment, and genotypes at approximately 110,000 gene-centric single-nucleotide polymorphisms (SNPs) were obtained by Illumina's Sentrix Human-1 Genotyping BeadChip. Statistical analyses were performed by the log-rank test and Cox proportional hazards model. RESULTS: From July 2002 to May 2004, 105 patients received a total of 308 cycles of treatment. The median survival time (MST) of 105 patients was 17.1 months. In the genome-wide association study, three SNPs were associated significantly with shortened OS after multiple comparison adjustment: rs1656402 in the EIF4E2 gene (MST was 18.0 and 7.7 months for AG [n = 50] + AA [n = 40] and GG [n = 15], respectively; p = 8.4 × 10-8), rs1209950 in the ETS2 gene (MST = 17.7 and 7.4 months for CC [n = 94] and CT [n = 11] + TT [n = 0]; p = 2.8 × 10 -7), and rs9981861 in the DSCAM gene (MST = 17.1 and 3.8 months for AA [n = 75] + AG [n = 26] and GG [n = 4]; p = 3.5 × 10-6). CONCLUSION: Three SNPs were identified as new prognostic biomarker candidates for advanced NSCLC treated with CBDCA and PTX. The agnostic genome-wide association study may unveil unexplored molecular pathways associated with the drug response, but our findings should be replicated by other investigators.
AB - PURPOSE: Our goal was to identify candidate polymorphisms that could influence overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with carboplatin (CBDCA) and paclitaxel (PTX). METHODS: Chemotherapy-naïve stage IIIB or IV NSCLC patients treated with CBDCA (area under the curve = 6 mg/mL/min) and PTX (200 mg/m2, 3-hour period) were eligible for this study. The DNA samples were extracted from peripheral blood mononuclear cells before treatment, and genotypes at approximately 110,000 gene-centric single-nucleotide polymorphisms (SNPs) were obtained by Illumina's Sentrix Human-1 Genotyping BeadChip. Statistical analyses were performed by the log-rank test and Cox proportional hazards model. RESULTS: From July 2002 to May 2004, 105 patients received a total of 308 cycles of treatment. The median survival time (MST) of 105 patients was 17.1 months. In the genome-wide association study, three SNPs were associated significantly with shortened OS after multiple comparison adjustment: rs1656402 in the EIF4E2 gene (MST was 18.0 and 7.7 months for AG [n = 50] + AA [n = 40] and GG [n = 15], respectively; p = 8.4 × 10-8), rs1209950 in the ETS2 gene (MST = 17.7 and 7.4 months for CC [n = 94] and CT [n = 11] + TT [n = 0]; p = 2.8 × 10 -7), and rs9981861 in the DSCAM gene (MST = 17.1 and 3.8 months for AA [n = 75] + AG [n = 26] and GG [n = 4]; p = 3.5 × 10-6). CONCLUSION: Three SNPs were identified as new prognostic biomarker candidates for advanced NSCLC treated with CBDCA and PTX. The agnostic genome-wide association study may unveil unexplored molecular pathways associated with the drug response, but our findings should be replicated by other investigators.
KW - Advanced non-small lung cancer
KW - Carboplatin
KW - Genome-wide association study
KW - Paclitaxel
KW - Single-nucleotide polymorphisms
UR - http://www.scopus.com/inward/record.url?scp=78651096047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651096047&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e318200f415
DO - 10.1097/JTO.0b013e318200f415
M3 - Article
C2 - 21079520
AN - SCOPUS:78651096047
SN - 1556-0864
VL - 6
SP - 132
EP - 138
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 1
ER -
